India is positioning itself as a global biomanufacturing hub with the launch of the BioE3 policy in 2024, which aims to create a $300 billion bioeconomy by 2030. The policy focuses on enhancing innovation in health, agriculture, clean energy, and sustainable manufacturing. India's response to the Covid-19 pandemic showcased its capabilities, as it became a leading vaccine supplier, administering over 2.2 billion doses between 2020 and 2022. Key players like the Serum Institute of India and Bharat Biotech contributed significantly to this success through public-private partnerships. However, the country faces challenges such as weak intellectual property regimes, fragmented regulations, and funding shortfalls. Addressing these issues is critical to fully realize India's potential in biotechnology and ensure its competitive edge in the global market.